Neovasc NVCN 深 滬
等待開盤 04-06 09:30:00 美东时间
30.03
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 30.03
- 總市值 8359.15万
- 52周最高 30.07
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 4.585
- 委 比 0.00%
- 總股本 278.36万
- 歷史最高 253000.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 7.25
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
Biogen to acquire Apellis for $41 per share, totaling approximately $5.6 billion, to gain two commercialized immunology medicines: EMPAVELI for rare kidney diseases and SYFOVRE for geographic atrophy. The deal, expected to close in 2Q2026, aims to boost Biogen's growth, with combined 2025 revenues of $689 million, projected to grow at mid-to-high teens through 2028. Apellis' capabilities will enhance Biogen's nephrology presence and support felza...
03-31 10:59
Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting
Apellis Pharmaceuticals will present eight abstracts at the 49th Macula Society Annual Meeting, highlighting five-year results from the GALE study demonstrating SYFOVRE's impact in delaying geographic atrophy (GA) progression. SYFOVRE, the first approved treatment for GA secondary to age-related macular degeneration, showed improved outcomes with early and continuous use. Other presentations include real-world treatment patterns, AI applications,...
02-19 12:00
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting
Kalaris Therapeutics announced that clinical data from its Phase 1 study of TH103, a novel therapy targeting VEGF and HSPG, will be presented at the 49th Macula Society Annual Meeting. The presentation, "First-in-Human Evaluation of TH103," will highlight safety, tolerability, pharmacokinetics, and early efficacy in treatment-naive neovascular AMD. Dean Eliott, MD, will present on February 26, 2026, in San Diego. Kalaris, founded by VEGF pioneer ...
01-28 21:05
BRIEF-Kalaris Begins Phase 1b/2 Study Of TH103 For Neovascular AMD With Multiple Ascending Dose Enrollment Underway
Sept 15 (Reuters) - Kalaris Therapeutics Inc KLRS.O: KALARIS THERAPEUTICS NOW ENROLLING PHASE 1B/2 MULTIPLE ASCENDING DOSE STUDY OF TH103 IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION KALARIS THERAP...
2025-09-15 20:08
Roche Holding AG Receives EU CE Mark for Contivue, Its Port Delivery Platform with Susvimo, for Treatment of Neovascular Age-Related Macular Degeneration
Roche Holding AG has announced that it has received the EU CE mark for its Port Delivery Platform containing Susvimo, which will be known as Contivue® in the European Union. This innovative device is ...
2025-09-04 14:00
Neovasc (NASDAQ:NVCN) Stock Passes Above 50 Day Moving Average of $29.44
Shares of Neovasc Inc. (NASDAQ:NVCN – Get Rating) (TSE:NVC) passed above its 50...
2023-04-27 18:00
Neovasc (NASDAQ:NVCN) Research Coverage Started at StockNews.com
StockNews.com began coverage on shares of Neovasc (NASDAQ:NVCN – Get Rating) (T...
2023-04-06 16:02
正面交锋调查：Alpha Tau Medical（纳斯达克股票代码：DRTS）vs.Neovasc（纳斯达克股票代码：NVCN）
Alpha Tau Medical (NASDAQ:DRTS – Get Rating) and Neovasc (NASDAQ:NVCN – Get Rat...
2023-03-09 15:44
Head-To-Head Comparison: IceCure Medical (NASDAQ:ICCM) Vs. Neovasc (NASDAQ:NVCN)
Neovasc (NASDAQ:NVCN – Get Rating) and IceCure Medical (NASDAQ:ICCM – Get Ratin...
2023-03-01 17:53
Neovasc Inc.（纳斯达克股票代码：NVCN）的空头利率增加了221.7％
Neovasc Inc. (NASDAQ:NVCN – Get Rating) (TSE:NVC) was the target of a large inc...
2023-02-11 13:28
